openPR Logo
Press release

Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial Infection to Drive Market

09-10-2018 09:05 AM CET | Health & Medicine

Press release from: Transparency Market Research

Bacterial Conjunctivitis Drugs Market: Rising Incidence

The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as AzaSite, Zymaxid, Moxeza, and Vigamox, are set to lose their marketing exclusivity very soon.

The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.

Obtain Report Details @ https://www.transparencymarketresearch.com/us-bacterial-conjunctivitis-drugs-market.html

Rising Prevalence of MDROs Creates Serious Challenge for Market’s Growth

Apart from this, the rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market’s growth over the coming years.

Although the market is facing a number of restraints at present, it may experience a little relief in future if the product development partnerships (PDPs) models for business are implemented by participants. As various research and development procedures incur a high amount, exerting substantial pressure on pharma companies, strategic alliances with small biotech research organizations will prove to be beneficial for both the parties.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12323

Market Encroachment by Generic Variations to Limit Demand for Topical Fluoroquinolones

Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. The demand for topical fluoroquinolones is the highest among all classes of bacterial conjunctivitis drugs in the U.S. However, the segment is projected to be hindered severely in the coming years, owing to the forthcoming patent expirations of bestselling drugs of this class, such as Vigamox, Moxeza, and Zymaxid by the end of 2016.

The market’s opportunity will also be hurt significantly over the next few years due to the encroachment by generic variations of these drugs and decline from US$361.9 mn in 2013 to US$286.4 mn by 2024.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12323

Imminent Patent Expiries to Hurt Leading Players Severely

Valeant Pharmaceuticals Int. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Perrigo Com. Plc., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Akorn Inc., and Actavis Plc. are leading the market for bacterial conjunctivitis drugs in the U.S. The imminent patent expiries is likely to hurt the business of these players significantly in the near future. However, the rising prevalence of bacterial infection in eyes and the increasing susceptibility to infection among individuals of various age groups may provide rewarding opportunities to participants over the next few years.

Players are recommended to focus on developing herbal medicines for the treatment of bacterial conjunctivitis, as the consumer preference is shifting from pharmacological medicines to herbal treatment regimens.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial Infection to Drive Market here

News-ID: 1228958 • Views: 195

More Releases from Transparency Market Research

Utility-Scale Energy Storage Technologies Market Advanced Technology and New Inn …
Global Utility-Scale Energy Storage Technologies Market: Overview The increasing demand for energy is accelerating the deployment of utility-scale energy storage technologies around the world. The benefits offered by these technologies in terms of increasing the efficiency of energy storage are projected to help the market grow in the near future. In addition, the rising demand for reducing the carbon footprint is expected to propel the growth of the global utility-scale energy
Corporate Travel Security Market to Witness an Outstanding Growth during 2019 …
Corporate Travel Security Market: Introduction Transparency Market Research delivers key insights on the corporate travel security market. In terms of revenue, the corporate travel security market is estimated to expand at a CAGR of ~4% during the forecast period, owing to numerous factors regarding which TMR offers thorough insights and forecasts in the corporate travel security market report. In the report, TMR predicts that the corporate travel security market would be
Distribution Automation Market Segmentation Application, Technology and Market A …
Global Distribution Automation Market: Overview Reaching a significant market worth by 2027, the global distribution automation market is set to chart a notable CAGR (Compound Annual Growth Rate) owing to an increase in generation of renewable energy, and a rising demand for energy efficiency. It is worth pointing out here that developing countries such as India are witnessing an increase in distributed energy generation and that is leading a plethora of untapped
Insulated Packaging Market Entry Strategies, Countermeasures of Economic Impact …
Insulated Packaging Market: Introduction Insulation material is defined as a material or combination of different materials having low thermal conductivity to resist the flow of heat. Thermal abuse is the major concern faced during the transportation of temperature sensible products; hence, most of the major industries such as food and beverages, pharmaceutical, healthcare, chemicals, cosmetics, etc., depend heavily on insulated materials for packaging. Products from these industries may be subjected to

All 5 Releases


More Releases for MDROs

A new formula against Multidrug-Resistant Organisms (MDROs)
Our DECONTAMAN PRE product range for skin and hand decontamination including hygienic, full body washing offers fast and complete efficacy as well as excellent skin compatibility. In order to meet the high standards and requirements of our customers and also their future needs, Dr. Schumacher GmbH has released updated and optimized formulations for the whole range. Infections in the medical sector caused by multidrug-resistant organisms (MDROs) pose a serious problem
Bacterial Conjunctivitis Drugs Market is set to garner staggering revenues by 2 …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as
Bacterial Conjunctivitis Drugs Market is likely to reduce to US$439.8 mn by 2024
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as
U.S. Bacterial Conjunctivitis Drugs Market 2024: Overview, Opportunities, In-Dep …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as
02-24-2017 | Health & Medicine
TMR
Bacterial Conjunctivitis Drugs Market: Rising Prevalence of MDROs Creates Seriou …
Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. Majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity. This study provides market analysis for various antibacterial drug classes used for the treatment of bacterial conjunctivitis. The stakeholders of this study comprise established pharmaceutical companies involved in
01-09-2017 | Health & Medicine
TMR
Bacterial Conjunctivitis Drugs Market: Rising Prevalence of MDROs Creates Seriou …
Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. Majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity. This study provides market analysis for various antibacterial drug classes used for the treatment of bacterial conjunctivitis. The stakeholders of this study comprise established pharmaceutical companies involved in